Treg dysfunction drives neuroinflammatory neurodegeneration
PrimaryCoya's central causal theory is that impaired regulatory T cell function contributes to chronic neuroinflammation in age-related neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's disease. If Tregs normally restrain harmful immune activation, then loss or dysfunction of Treg activity should permit inflammatory monocytes, macrophages, microglia, and effector T cell responses to accelerate neuronal injury and clinical decline. A testable prediction is that patients with worse Treg dysfunction should show faster disease progression or more severe neuroinflammatory biomarkers, while interventions that restore Treg number or suppressive function should reduce inflammatory biomarkers and slow functional decline.
Popperian evaluation
The premise is biologically credible. Tregs normally restrain immune activation, and the evidence context links Treg dysfunction to ALS progression, regulatory immune impairment in untreated Parkinson's disease, and altered Treg profiles in Alzheimer's disease. The weak point is causality across diseases: ALS has the cleanest human correlation, while Alzheimer's and Parkinson's evidence looks broader and more mixed. Treg dysfunction may be one driver of neuroinflammation, but the provided evidence does not prove it is the initiating driver.
Supporting evidence: ALS patients are reported to have dysfunctional regulatory T lymphocytes, with dysfunction correlating with disease progression rate and severity.; Untreated Parkinson's disease shows regulatory immune impairment involving Tregs and other regulatory populations.; Regulatory T cell profile changes have been characterized in Alzheimer's disease.; The theory includes a coherent mechanism: impaired suppressive Treg activity permits monocytes, macrophages, microglia, and effector T cells to remain activated.
Counter evidence: Parkinson's disease evidence is not restricted to Tregs, which weakens a Treg-centered causal claim.; Alzheimer's disease evidence is described as profile changes consistent with immune dysregulation, which is weaker than direct causal evidence.; Measured Treg number, phenotype, or suppressive function is only a medium-confidence proxy for disease-relevant regulatory activity.
The theory explains a real pattern: worse regulatory immune control could plausibly track with higher neuroinflammatory biomarkers and faster decline. It fits ALS especially well because the provided evidence ties Treg dysfunction to progression rate and severity. But it does not yet beat alternative explanations cleanly. Neurodegeneration can itself disturb immune regulation, and microglial activation, protein aggregation, mitochondrial stress, vascular injury, and peripheral inflammation could all produce overlapping biomarker signals. The theory is useful, but it is not yet the boss of the evidence.
Supporting evidence: The ALS observation directly matches the prediction that worse Treg dysfunction should associate with faster progression.; Preclinical Parkinson's disease models show neuroprotective or anti-neuroinflammatory effects from Treg-enhancing or Treg-transfer approaches.; Preclinical Alzheimer's disease models show neuroprotective or neuroinflammation-modifying effects from Treg-based approaches.; The theory connects peripheral immune regulation to monocytes, macrophages, microglia, effector T cells, neuronal injury, and clinical decline.
Counter evidence: The evidence context does not show that Treg dysfunction precedes neurodegeneration in humans.; Several diseases are grouped together, but ALS, Alzheimer's disease, and Parkinson's disease have different initiating pathologies.; Alternative inflammatory mechanisms could explain the same observations without making Treg dysfunction the central causal driver.
The theory is testable. It predicts that patients with worse Treg dysfunction should have faster clinical decline or stronger neuroinflammatory biomarkers, and that restoring Treg number or suppressive function should reduce inflammatory biomarkers and slow functional decline. Those claims can fail in longitudinal cohorts and randomized intervention trials. The main caveat is measurement: if Treg phenotype, Treg suppressive assays, biomarkers, and clinical endpoints are noisy, a failed test could be blamed on the assay instead of the theory.
Supporting evidence: The theory states a directional patient-level prediction: worse Treg dysfunction should track with faster progression or more severe neuroinflammatory biomarkers.; The intervention prediction is concrete: Treg restoration should reduce inflammatory biomarkers and slow functional decline.; IL-2-based approaches and ex vivo expanded Tregs provide intervention routes that can test the mechanism.; The evidence context explicitly names biomarker and clinical progression measures as required readouts.
Counter evidence: The proxy problem is real: measured Treg number, phenotype, or suppressive function may not capture the regulatory activity relevant inside the nervous system.; Clinical progression measures in neurodegenerative disease can be variable and may require large or long trials to detect a causal effect.; If multiple regulatory immune populations change together, isolating Treg-specific falsification becomes harder.
Reasoning tree
Public endorsements
The dossier ties Anabella Villalobos to Coya through a 2021 board appointment and describes her broader drug-discovery leadership, but it does not show a public statement from her endorsing, discussing, or disputing Coya's theory that Treg dysfunction drives neuroinflammatory neurodegeneration.
Arun Swaminathan publicly ties Coya to "Treg-targeted therapies" across ALS, FTD, Parkinson's, and Alzheimer's, and he frames the company's science as part of its investor case. That is a public mention of the Treg-centered program. The evidence here does not show him explicitly stating the full causal theory that Treg dysfunction drives neuroinflammatory neurodegeneration, so "publicly_endorses" would go too far.
Arun Swaminathan is publicly tied to Coya's Treg-based neurodegeneration program in a September 4, 2025 Q&A titled "Targeting Neurodegenerative Diseases Through Treg Therapies." That is a public mention of the theory area, but the provided evidence does not include a direct statement from him endorsing the full causal claim that Treg dysfunction drives neuroinflammatory neurodegeneration.
Evidence publication IDs: bd4af2f1-c9f0-4d09-9467-bed57e7e8f35
Berman publicly ties Coya to Treg-based therapies and neurodegenerative disease, and he explicitly praised Treg-derived exosomes as an immunosuppression approach. That is directionally aligned with the theory. The evidence here does not show him plainly stating the full causal claim that Treg dysfunction drives neuroinflammatory neurodegeneration, so this is a mention rather than a clean public endorsement.
Evidence publication IDs: 94e5ee57-fa86-43e3-8981-73f8fbace792, c0c43036-5d64-4189-b08a-0c70dc079839
The record shows Mark Pavao is publicly listed in connection with Coya, and a separate quote shows him discussing an investment in 4M Therapeutics, not Coya's Treg dysfunction theory in neurodegeneration. In the evidence provided here, he does not publicly endorse, describe, or dispute Coya's causal claim about impaired Treg function driving neuroinflammatory neurodegeneration.
Evidence publication IDs: 3e0db154-e03e-4e18-a3db-3da940ccd6fe, 6fe45a3f-112e-4f52-8da6-c6853ecc4a8c